| human | Q5 |
| P11723 | IRIS HUNIMED author ID | 00769 |
| P496 | ORCID iD | 0000-0003-1709-9492 |
| P1053 | ResearcherID | J-9594-2018 |
| P396 | SBN author ID | BVEV013965 |
| P69 | educated at | University of Messina | Q1245318 |
| Stanford University School of Medicine | Q4115969 | ||
| P108 | employer | National Cancer Institute | Q3747179 |
| Humanitas Research Hospital | Q3803602 | ||
| P734 | family name | Santoro | Q28797468 |
| Santoro | Q28797468 | ||
| Santoro | Q28797468 | ||
| P735 | given name | Armando | Q18177180 |
| Armando | Q18177180 | ||
| P106 | occupation | researcher | Q1650915 |
| P5008 | on focus list of Wikimedia project | WikiProject COVID-19 | Q87748614 |
| P21 | sex or gender | male | Q6581097 |
| Q46909910 | 11C-labeled methionine and evaluation of malignant pleural mesothelioma |
| Q87438374 | A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer |
| Q40224897 | A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma |
| Q46454840 | A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. |
| Q38425167 | A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. |
| Q89898137 | A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma |
| Q45179487 | A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. |
| Q46491015 | A prospective study on survival in cancer patients with and without venous thromboembolism |
| Q44253334 | A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy |
| Q45945682 | A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. |
| Q53349399 | A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. |
| Q41652822 | A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study |
| Q88396394 | A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling |
| Q40102832 | ABVD chemotherapy in the treatment of Hodgkin's disease. |
| Q34253748 | Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. |
| Q27853360 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial |
| Q45919728 | Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. |
| Q96763554 | Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study |
| Q44354605 | Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. |
| Q52686844 | Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. |
| Q92020462 | Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation |
| Q43476617 | Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme |
| Q84179330 | Advanced colorectal liver metastases and surgery after preoperative chemotherapy: is response-based selection enough? |
| Q37834758 | Advances in the biology of malignant pleural mesothelioma |
| Q35566453 | Advances in the treatment of Hodgkin's disease |
| Q83474458 | Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma |
| Q50703278 | Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. |
| Q37470361 | An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers |
| Q42630651 | An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy |
| Q36695371 | Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer |
| Q48720736 | Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique. |
| Q42366567 | Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study |
| Q35227986 | Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment |
| Q40619773 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications |
| Q35886218 | Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience |
| Q36926206 | Assessment of tumor response in malignant pleural mesothelioma |
| Q43160222 | Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. |
| Q53174548 | B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). |
| Q59116692 | B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY |
| Q55077625 | BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL. |
| Q57690133 | BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients |
| Q33415782 | Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation |
| Q58924276 | Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi |
| Q33433659 | Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. |
| Q60171309 | Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma |
| Q45375185 | Beyond semantics: the need to better categorize patients with cancer |
| Q54271712 | Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. |
| Q61054507 | Biomarkers in Hepatocellular Carcinoma--Letter |
| Q87297876 | Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide |
| Q53163203 | Bone marrow donor-related variables associated with harvest outcome in HLA-haploidentical transplantation with postinfusion cyclophosphamide. |
| Q66698077 | Bone-marrow patterns and clinical staging in chronic lymphocytic leukaemia |
| Q38551290 | Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper |
| Q47563175 | Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma |
| Q33420273 | Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers |
| Q37060652 | Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials |
| Q92509009 | Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer |
| Q39465495 | CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer |
| Q56942543 | CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study |
| Q40457312 | CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. |
| Q95323809 | COVID-19 and liver cancer clinical trials: not everything is lost |
| Q90648721 | Cabozantinib for the treatment of hepatocellular carcinoma |
| Q42364897 | Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. |
| Q44315537 | Cancer patients and survivors: changing words or changing culture? |
| Q78630092 | Cardiac involvement in non-Hodgkin's lymphoma |
| Q43020298 | Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer |
| Q91176661 | Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide |
| Q40202331 | Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study |
| Q27852989 | Ceritinib in ALK-rearranged non-small-cell lung cancer |
| Q29616236 | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer |
| Q46243039 | Characterisation of the immune-related transcriptome in resected biliary tract cancers |
| Q99583891 | Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? |
| Q52315726 | Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer? |
| Q51780875 | Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin. |
| Q33371199 | Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study |
| Q37146056 | Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up |
| Q38442976 | Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. |
| Q61986469 | Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients |
| Q92224914 | Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study |
| Q47691708 | Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologi |
| Q53275651 | Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. |
| Q38909086 | Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. |
| Q36064817 | Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series. |
| Q40688498 | Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. |
| Q36028504 | Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide |
| Q37639132 | Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. |
| Q96637722 | Copanlisib for the treatment of adults with relapsed follicular lymphoma |
| Q63582167 | Copanlisib in patients with relapsed or refractory follicular lymphoma |
| Q36121767 | Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. |
| Q50634571 | Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. |
| Q42667210 | Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). |
| Q38368587 | Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. |
| Q48101262 | Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System |
| Q90880807 | Delayed childbearing and female ageing impair assisted reproductive technology outcome in survivors of male haematological cancers |
| Q50914957 | Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation. |
| Q90242732 | Development of an immobilization device for Total Marrow Irradiation |
| Q92074935 | Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes |
| Q33488674 | Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group |
| Q52873305 | Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. |
| Q39263090 | Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation. |
| Q54499342 | Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. |
| Q52653458 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. |
| Q84709396 | ECIL 3-2009 update guidelines for antifungal management |
| Q62991747 | EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients |
| Q34572048 | EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma. |
| Q45993942 | Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. |
| Q34283052 | Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients |
| Q37938185 | Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group |
| Q59647703 | Early lesions in lymphomas of germinal centre B-cell derivation: evidence and hypotheses |
| Q79157134 | Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose |
| Q84534603 | Early surgical experience with minimally invasive percutaneous approach for patients with metastatic epidural spinal cord compression (MESCC) to poor prognoses |
| Q61054481 | Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study |
| Q34663499 | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial |
| Q54303287 | Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung c |
| Q44089673 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial |
| Q34674564 | Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma |
| Q61054490 | Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? |
| Q39677074 | Expression and mutational status of c-kit in thymic epithelial tumors |
| Q53550371 | FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. |
| Q39031946 | Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). |
| Q85281015 | Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available |
| Q61054511 | Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection |
| Q92413781 | Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer |
| Q61054503 | Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer |
| Q81071045 | First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma |
| Q54628564 | First-line extracorporeal photochemotherapy for acute GVHD after unmanipulated haploidentical BMT following nonmyeloablative conditioning and post transplantation CY. |
| Q92626998 | Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma |
| Q38930717 | Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. |
| Q33382912 | Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). |
| Q44415170 | Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics |
| Q54600310 | Fulvestrant for advanced male breast cancer patients: a case series. |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q33378691 | Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma |
| Q81405822 | Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up |
| Q45353745 | Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases |
| Q52659308 | Genomic Integration of HHV-6 Mimicking Viral Reactivation after Autologous Stem Cell Transplantation. |
| Q101560629 | Haploidentical Stem Cell Transplantation in Lymphomas-Expectations and Pitfalls |
| Q87980114 | Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma |
| Q54686087 | Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. |
| Q80643017 | Herpes infections in breast cancer patients treated with adjuvant chemotherapy |
| Q46027432 | High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. |
| Q46944596 | High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma. |
| Q37066558 | High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review. |
| Q73893342 | High-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly versus younger lymphoma patients: a matched analysis |
| Q41525624 | High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant |
| Q53276110 | How I treat: diagnosing and managing "in situ" lymphoma. |
| Q40806185 | Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study |
| Q50124280 | Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. |
| Q50095722 | Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series. |
| Q34295696 | Identifying and targeting ROS1 gene fusions in non-small cell lung cancer |
| Q38357146 | Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. |
| Q44622664 | Idiopathic thrombocytopenic purpura and splenic marginal-zone B-cell lymphoma: a casual correlation? |
| Q33373887 | Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma |
| Q62512297 | Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients |
| Q37874211 | In situ follicular lymphoma: pathologic characteristics and diagnostic features. |
| Q35926926 | Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients |
| Q35149263 | Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. |
| Q41484569 | Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. |
| Q39002523 | Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue. |
| Q44743006 | Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. |
| Q35994860 | Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. |
| Q34675581 | Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas |
| Q92605351 | Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction |
| Q35925639 | Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. |
| Q48488244 | Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma |
| Q79329009 | Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? |
| Q91876548 | Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question |
| Q92319142 | Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases |
| Q57464300 | Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma |
| Q47130656 | Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma |
| Q90182576 | KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study |
| Q36528345 | KRAS mutation in lung metastases from colorectal cancer: prognostic implications |
| Q34273793 | Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc |
| Q48163012 | Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. |
| Q90466668 | Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial |
| Q51733625 | Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. |
| Q54445262 | Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy. |
| Q81711846 | Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer |
| Q38373761 | Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography |
| Q50086144 | Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303. |
| Q92198509 | Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study |
| Q51223611 | Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications. |
| Q36502159 | Lung cancer in which the hypothesis of multi-step progression is confirmed by array-CGH results: A case report. |
| Q98208300 | Lung cancer management: monitoring and treating resistance development in third generation EGFR TKIs |
| Q39737533 | Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials. |
| Q36971113 | Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. |
| Q90732464 | Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial |
| Q49374190 | Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma |
| Q89770376 | Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study |
| Q48156165 | Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. |
| Q53033550 | MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. |
| Q38557033 | Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma |
| Q43830902 | Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma |
| Q36051526 | Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma |
| Q43508188 | Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. |
| Q63283118 | Monoclonal antibodies and therapy of human cancers |
| Q46339997 | Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. |
| Q34659099 | Multidisciplinary treatment of malignant pleural mesothelioma |
| Q61986557 | Multimodal Approach to the Management of Metastatic Epidural Spinal Cord Compression (MESCC) Due to Solid Tumors |
| Q35676452 | Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. |
| Q46704083 | Neutropenic enterocolitis: is there a right timing for surgery? Assessment of a clinical case. |
| Q51737415 | Never too old to fight breast cancer: A case report. |
| Q43071581 | New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma |
| Q92523342 | Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study |
| Q56383260 | Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial |
| Q38906747 | Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial |
| Q92745852 | Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience |
| Q61447502 | Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial |
| Q47139758 | Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. |
| Q85312715 | Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas |
| Q92962188 | Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma |
| Q51110465 | Olfactory system of highly trained dogs detects prostate cancer in urine samples. |
| Q33421897 | Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q42740868 | Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib |
| Q24814155 | Oral ulcer as an exclusive sign of gastric cancer: report of a rare case |
| Q47350303 | Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis |
| Q47426457 | Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. |
| Q50526883 | Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. |
| Q57972679 | Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy |
| Q51769462 | Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. |
| Q94510962 | PD-1 Blockade in Anaplastic Thyroid Carcinoma |
| Q92641629 | PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy |
| Q39805430 | PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. |
| Q48387795 | Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. |
| Q40371676 | Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support |
| Q93147870 | Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study |
| Q33379936 | Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. |
| Q34791118 | Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program |
| Q46893703 | Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. |
| Q92289372 | Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma |
| Q34964958 | Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors |
| Q36557802 | Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours |
| Q57972640 | Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors |
| Q33433311 | Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. |
| Q40385132 | Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas |
| Q36368120 | Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments |
| Q52750601 | Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. |
| Q46054785 | Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. |
| Q61054513 | Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy |
| Q54301822 | Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. |
| Q43091608 | Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma |
| Q91066165 | Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis |
| Q37081896 | Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma |
| Q82892136 | Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma |
| Q80112177 | Phase II study of sorafenib in patients with advanced hepatocellular carcinoma |
| Q80494703 | Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer |
| Q62392233 | Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer |
| Q53428610 | Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. |
| Q61628274 | Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial |
| Q33388979 | Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy |
| Q46674520 | Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma |
| Q39576387 | Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer |
| Q37287413 | Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours |
| Q117442360 | Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma |
| Q47701191 | Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma |
| Q36094726 | Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. |
| Q86831208 | Post-remission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age ≥75 years: a retrospective analysis of the Rete Ematologica Lombarda |
| Q91558896 | Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction |
| Q84792042 | Postoperative chemoradiotherapy or surgery alone for gastric cancer: the plausibility of the question and pertinence of the answer |
| Q51019986 | Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience. |
| Q53247406 | Preclinical assessment of volumetric modulated arc therapy for total marrow irradiation. |
| Q39463417 | Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin |
| Q90418722 | Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients |
| Q46062506 | Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. |
| Q91188685 | Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide |
| Q36615222 | Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study |
| Q92088392 | Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report |
| Q38466376 | Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. |
| Q36755257 | Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients |
| Q42373344 | Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. |
| Q38493294 | Prognostic and predictive value of MET deregulation in non-small cell lung cancer |
| Q89643822 | Prognostic factors and outcome of HER2+ breast cancer with CNS metastases |
| Q34504714 | Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and |
| Q33918135 | Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey |
| Q41942214 | Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma |
| Q52682078 | Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? |
| Q33398899 | Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients |
| Q41957527 | Prostatic stromal tumor with fatal outcome in a young man: histopathological and immunohistochemical case presentation. |
| Q92495187 | Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: A case report on the therapeutic regimen |
| Q48482267 | Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study |
| Q45020726 | Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. |
| Q38938622 | Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? |
| Q38186853 | Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas |
| Q51021033 | Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. |
| Q43582917 | Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure |
| Q38432288 | Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer |
| Q43728324 | Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study |
| Q61986567 | Re-irradiation of metastatic spinal cord compression: A feasibility study by volumetric-modulated arc radiotherapy for in-field recurrence creating a dosimetric hole on the central canal |
| Q44029160 | Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six cases |
| Q34546077 | Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer |
| Q44119537 | Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas |
| Q80557773 | Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer |
| Q79663005 | Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion |
| Q38264146 | Refining sorafenib therapy: lessons from clinical practice. |
| Q42606277 | Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study |
| Q38674803 | Regorafenib for the treatment of unresectable hepatocellular carcinoma. |
| Q91352542 | Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) |
| Q61054508 | Reply to Y. Pointreau et al |
| Q36617625 | Reproducibility of the WHO classification of thymomas: practical implications |
| Q33430547 | Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. |
| Q54597286 | Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma. |
| Q57758330 | Response: Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial |
| Q83153976 | Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma |
| Q45765239 | Retroperitoneal Sarcoma: Is It Time to Change the Surgical Policy? |
| Q50108333 | Retroperitoneal sarcoma: is it time to change the surgical policy? |
| Q81248061 | Rituximab in thrombotic microangiopathy |
| Q44423483 | Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors |
| Q35584266 | Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. |
| Q39202948 | Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study |
| Q50454368 | SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. |
| Q60685569 | STAGING FOR CHRONIC LYMPHOCYTIC LEUKÆMIA |
| Q47169813 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. |
| Q101227870 | Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes |
| Q44343748 | Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. |
| Q37625063 | Second-line treatment for malignant pleural mesothelioma |
| Q48256316 | Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL). |
| Q80674088 | Short schedule of cisplatin and vinorelbine: a dose-finding study in non-small-cell lung cancer |
| Q80055929 | Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen |
| Q112608461 | Single-cell profiling defines the prognostic benefit of CD39high tissue resident memory CD8+ T cells in luminal-like breast cancer |
| Q40215577 | Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! |
| Q27861075 | Sorafenib in advanced hepatocellular carcinoma |
| Q57758019 | Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis |
| Q46124730 | Sorafenib is active on lung metastases from synovial sarcoma |
| Q45982820 | Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. |
| Q28235646 | Sorafenib: a review of its use in advanced hepatocellular carcinoma |
| Q43211029 | Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. |
| Q34196471 | Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach |
| Q53026075 | Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. |
| Q40831744 | Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. |
| Q61986543 | Surgery Followed by Radiotherapy for the Treatment of Metastatic Epidural Spinal Cord Compression From Breast Cancer |
| Q90495861 | Survival Outcome and Prognostic Factors After Pulmonary Metastasectomy in Sarcoma Patients: A 18-Year Experience at a Single High-volume Referral Center |
| Q91222441 | Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer |
| Q48583550 | T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identica |
| Q41138074 | T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. |
| Q86765425 | Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide |
| Q44634053 | Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma |
| Q43234207 | Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. |
| Q48362187 | Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. |
| Q40468321 | Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. |
| Q38400475 | Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports. |
| Q57796532 | Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530 |
| Q46979293 | The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas |
| Q42937122 | The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo |
| Q87926401 | The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide |
| Q92224919 | The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments |
| Q52560280 | The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation. |
| Q43280955 | The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial |
| Q61054522 | The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study |
| Q48124038 | The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. |
| Q54633112 | The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. |
| Q37765048 | The present and the future landscape of treatment of advanced hepatocellular carcinoma. |
| Q46893706 | The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer. |
| Q38211083 | The role of inflammation in lymphoma. |
| Q46638000 | The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. |
| Q89730356 | The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art |
| Q33343719 | Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study |
| Q90317011 | Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer |
| Q57890679 | Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin |
| Q84179599 | Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy |
| Q42710714 | Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter |
| Q61054502 | Tivantinib for hepatocellular carcinoma |
| Q56384328 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study |
| Q38062681 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. |
| Q91323635 | Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial |
| Q55062173 | Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers. |
| Q39466467 | Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma |
| Q38872192 | Trabectedin for the treatment of soft tissue sarcomas. |
| Q54654322 | Trastuzumab beyond progression: a challenge to translational oncology? |
| Q37687269 | Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib |
| Q42292467 | Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. |
| Q41701253 | Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis |
| Q44325865 | Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer |
| Q50588099 | Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. |
| Q55089546 | Unsupervised versus Supervised Identification of Prognostic Factors in Patients with Localized Retroperitoneal Sarcoma: A Data Clustering and Mahalanobis Distance Approach. |
| Q56335953 | Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme |
| Q53097045 | Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. |
| Q124137704 | Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer |
| Q61986533 | Vertebral metastases reirradiation with volumetric-modulated arc radiotherapy |
| Q39292744 | Vertebroplasty for pain relief and spinal stabilization in multiple myeloma |
| Q86920950 | Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma |
| Q38465861 | Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice |
| Q61986563 | Volumetric Modulation Arc Radiotherapy Compared With Static Gantry Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma Tumor: A Feasibility Study |
Search more.